A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.
Biologic therapy
Direct costs
Health-related quality of life
Healthcare resource utilization
Indirect costs
Systematic literature review
Ulcerative colitis
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
03
11
2022
accepted:
06
03
2023
medline:
17
5
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
The clinical benefits of advanced therapies (i.e., biologics and small-molecule drugs) in the treatment of moderate-to-severe ulcerative colitis (UC) have been demonstrated; however, there is less clarity regarding the economic and health-related quality of life (HRQoL) impact of these treatments. We conducted a systematic literature review to synthesize data on cost, healthcare resource utilization (HCRU), and HRQoL for patients who received approved advanced therapies for moderate-to-severe UC in the United States and Europe. Databases including MEDLINE, Embase, the Database of Abstracts of Reviews of Effects (DARE), the National Health Service Economic Evaluation Database (NHS EED), and EconLit were searched systematically to identify observational studies published between January 1, 2010 and October 14, 2021 that assessed the impact of advanced therapies on cost, HCRU, and/or HRQoL in adults with moderate-to-severe UC. Supplementary gray literature searches of conference proceedings from the past 4 years (January 2018 to October 2021) were also performed. 47 publications of 40 unique cost/HCRU studies and 13 publications of nine unique HRQoL studies were included. Findings demonstrated that biologics have a positive impact on indirect costs (i.e., productivity, presenteeism, and absenteeism) and HRQoL. High costs of biologics were not always fully offset by reductions in cost and HCRU associated with disease management. For many patients, treatment switching and dose escalations were required, thus increasing drug costs, particularly when switching across treatment classes. These findings highlight a high unmet need for therapies for moderate-to-severe UC that can reduce the healthcare burden and impact on society. Further research is warranted, as the reported evidence was limited by the small sample sizes of some treatment groups within a study. Although advanced therapies, such as biologics and small-molecule drugs, have shown clinical benefit in treating moderate-to-severe ulcerative colitis, their economic impact and effect on patients’ quality of life is less clear. This study comprehensively reviewed the cost and use of healthcare resources associated with starting treatment with advanced therapies for ulcerative colitis, as well as the impact of these treatments on quality of life. We found that while biologics have a benefit on work productivity, work attendance, work absence, and quality of life, the high costs of biologics were not always fully met by reductions in disease management costs and healthcare resources. Many patients needed to switch treatments or required dose increases, which were expensive. There is a high unmet need for therapies for moderate-to-severe ulcerative colitis that can reduce healthcare costs, use of healthcare resources, and effect on society.
Autres résumés
Type: plain-language-summary
(eng)
Although advanced therapies, such as biologics and small-molecule drugs, have shown clinical benefit in treating moderate-to-severe ulcerative colitis, their economic impact and effect on patients’ quality of life is less clear. This study comprehensively reviewed the cost and use of healthcare resources associated with starting treatment with advanced therapies for ulcerative colitis, as well as the impact of these treatments on quality of life. We found that while biologics have a benefit on work productivity, work attendance, work absence, and quality of life, the high costs of biologics were not always fully met by reductions in disease management costs and healthcare resources. Many patients needed to switch treatments or required dose increases, which were expensive. There is a high unmet need for therapies for moderate-to-severe ulcerative colitis that can reduce healthcare costs, use of healthcare resources, and effect on society.
Identifiants
pubmed: 37000363
doi: 10.1007/s12325-023-02488-z
pii: 10.1007/s12325-023-02488-z
pmc: PMC10130125
doi:
Substances chimiques
Biological Products
0
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2116-2146Informations de copyright
© 2023. The Author(s).
Références
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–25.
pubmed: 22047562
doi: 10.1056/NEJMra1102942
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94.
pubmed: 21530745
doi: 10.1053/j.gastro.2011.01.055
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–78.
pubmed: 29050646
doi: 10.1016/S0140-6736(17)32448-0
Burri E, Maillard MH, Schoepfer AM, et al. Treatment algorithm for mild and moderate-to-severe ulcerative colitis: an update. Digestion. 2020;101(suppl 1):2–15.
pubmed: 31945767
doi: 10.1159/000504092
Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2(4884):375–8.
pubmed: 13182220
pmcid: 2078989
doi: 10.1136/bmj.2.4884.375
Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13(3):273–84.
pubmed: 30137278
doi: 10.1093/ecco-jcc/jjy114
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9.
pubmed: 3317057
doi: 10.1056/NEJM198712243172603
Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–61.
pubmed: 31945371
doi: 10.1053/j.gastro.2020.01.006
Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgrad Med. 2017;129(5):538–53.
pubmed: 28425825
doi: 10.1080/00325481.2017.1319730
Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17.
pubmed: 34635919
doi: 10.1093/ecco-jcc/jjab178
Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25(3):453–68.
pubmed: 20370724
doi: 10.1111/j.1440-1746.2010.06241.x
Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–70.
pubmed: 34856198
doi: 10.1016/S2468-1253(21)00377-0
Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS ONE. 2020;15(1): e0227914.
pubmed: 31945774
pmcid: 6964980
doi: 10.1371/journal.pone.0227914
Gemayel NC, Rizzello E, Atanasov P, Wirth D, Borsi A. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Curr Med Res Opin. 2019;35(11):1911–23.
pubmed: 31192706
doi: 10.1080/03007995.2019.1631058
Crohn’s & Colitis Foundation. Fact sheet: News from the IBD Help Center - recently approved treatments. https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/recently-approved-treatments.pdf . Accessed April 10, 2022.
Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond). 2021;21(2):135–9.
pubmed: 33762374
doi: 10.7861/clinmed.2021-0080
Tazi J, Begon-Pescia C, Campos N, Apolit C, Garcel A, Scherrer D. Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases. Drug Discov Today. 2021;26(4):1030–9.
pubmed: 33387693
doi: 10.1016/j.drudis.2020.12.019
Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550–61.
pubmed: 31711921
doi: 10.1053/j.gastro.2019.10.035
Vermeire S, Hebuterne X, Tilg H, et al. Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase IIa trial. Gastroenterology. 2021;160(7):2595–8.
pubmed: 33662385
doi: 10.1053/j.gastro.2021.02.054
Leber A, Hontecillas R, Zoccoli-Rodriguez V, et al. The safety, tolerability, and pharmacokinetics profile of BT-11, an oral, gut-restricted lanthionine synthetase C-like 2 agonist investigational new drug for inflammatory bowel disease: a randomized, double-blind, placebo-controlled phase I clinical trial. Inflamm Bowel Dis. 2020;26(4):643–52.
pubmed: 31077582
Danese S, Klopocka M, Scherl EJ, et al. Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study. Clin Gastroenterol Hepatol. 2021;19(11):2324–32.
pubmed: 34126262
doi: 10.1016/j.cgh.2021.06.011
RINVOQ (upadacitinib) [summary of product characteristics]. AbbVie Deutschland GmbH & Co. KG: Ludwigshafen, Germany; December 2019.
RINVOQ (upadacitinib) extended-release tablets, for oral use. AbbVie Biotechnology, Ltd.: North Chicago, IL; April 2022.
XELJANZ (tofacitinib) [summary of product characteristics]. Pfizer Europe MA EEIG: Brussels, Belgium; March 2022.
XELJANZ (tofacitinib) oral solution. Pfizer, Inc.: New York, NY; December 2021.
ZEPOSIA (ozanimod) [summary of product characteristics]. Bristol Myers Squibb Pharma EEIG: Dublin, Ireland; December 2021.
ZEPOSIA (ozanimod) capsules, for oral use. Celgene Corporation, a member of the Bristol Myers Squibb group: Summit, NJ; April 2022.
Long GH, Tatro AR, Oh YS, Reddy SR, Ananthakrishnan AN. Analysis of safety, medical resource utilization, and treatment costs by drug class for management of inflammatory bowel disease in the United States based on insurance claims data. Adv Ther. 2019;36(11):3079–95.
pubmed: 31562607
pmcid: 6822802
doi: 10.1007/s12325-019-01095-1
Long MD, Smith TW, Dibonaventura M, et al. Real-world effectiveness of advanced therapies among patients with moderate to severe ulcerative colitis in the United States. Inflamm Bowel Dis. 2020;26(6):941–8.
pubmed: 31560046
doi: 10.1093/ibd/izz204
Carter CT, Leher H, Smith P, Smith DB, Waters HC. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care. 2011;17(6):385–92.
pubmed: 21756009
Campbell-Hill S, Stein D, Soni M, et al. Real-world drug treatment costs for ulcerative colitis and Crohn’s disease patients treated with vedolizumab vs anti-TNFalpha: results from a German retrospective chart review study. J Crohns Colitis. 2018;12(suppl 1):S504.
Armuzzi A, Marchi S, Gasbarrini A, et al. GO-CARE: a prospective multi-centre observational study of golimumab effectiveness and quality of life in a real-life UC patient population in Italy. J Crohns Colitis. 2018;12(suppl 1):S497.
Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139–78.
pubmed: 31440029
pmcid: 6679695
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.
pubmed: 26030634
doi: 10.7326/M14-2385
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
pubmed: 19621072
pmcid: 2707599
doi: 10.1371/journal.pmed.1000097
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3): e1003583.
pubmed: 33780438
pmcid: 8007028
doi: 10.1371/journal.pmed.1003583
Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2–10.
Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed: The Cochrane Collaboration; 2019.
Teich N, Grummer H, Jorgensen E, et al. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months. BMC Gastroenterol. 2021;21(1):161. https://doi.org/10.1186/s12876-021-01747-z .
doi: 10.1186/s12876-021-01747-z
pubmed: 33845784
pmcid: 8042988
Teich N, Grummer H, Jorgensen E, et al. Golimumab in real-world practice in patients with ulcerative colitis: twelve-month results. World J Gastroenterol. 2020;26(21):2852–63.
pubmed: 32550760
pmcid: 7284175
doi: 10.3748/wjg.v26.i21.2852
van der Valk ME, Mangen MJ, Severs M, et al. Comparison of costs and quality of life in ulcerative colitis patients with an ileal pouch-anal anastomosis, ileostomy and anti-TNFα therapy. J Crohns Colitis. 2015;9(11):1016–23.
pubmed: 26254056
doi: 10.1093/ecco-jcc/jjv134
Teich N, Gruemmer H, Joergensen E, et al. Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany. J Crohns Colitis. 2019;13(suppl 1):S337–8.
doi: 10.1093/ecco-jcc/jjy222.577
van Gennep S, Sahami S, Buskens CJ, et al. Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy. Eur J Gastroenterol Hepatol. 2017;29(3):338–44.
pubmed: 27902515
doi: 10.1097/MEG.0000000000000798
Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Kim SC, Schneeweiss S. Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: infliximab with thiopurines compared to infliximab monotherapy. Pharmacoepidemiol Drug Saf. 2021;08:08.
Bornheimer R, Hass S, Nag A, Oster G. Economic burden of biologic treatment in patients with inflammatory bowel disease in the US. Am J Gastroenterol. 2019;114(suppl):S433–44.
doi: 10.14309/01.ajg.0000592484.27433.a0
Borren NZ, Tan W, Colizzo FP, et al. Longitudinal trajectory of fatigue with initiation of biologic therapy in inflammatory bowel diseases: a prospective cohort study. J Crohns Colitis. 2020;14(3):309–15.
pubmed: 31504365
doi: 10.1093/ecco-jcc/jjz148
Cai Q, Ding Z, Teeple A, Gowda P, Muser E. Costs of inflammatory bowel disease-related hospitalizations and surgeries: a retrospective analysis in a commercially insured population S0871. Am J Gastroenterol. 2020;115(suppl):S449.
doi: 10.14309/01.ajg.0000705532.18543.be
Chapman JC, DiBonaventura MD, Comerford E, et al. Extraintestinal manifestations and their impact on real-world treatment patterns and outcomes among patients with ulcerative colitis. Gastroenterology. 2019;156(suppl 3):S47–8.
doi: 10.1053/j.gastro.2019.01.127
Chen J, Zhao Y, Liu T, Candela N, Lasch K. P477 Assessment of treatment sequence and real-world outcomes in patients with ulcerative colitis. J Crohns Colitis. 2021;15(suppl 1):S466–7.
doi: 10.1093/ecco-jcc/jjab076.600
Chiorean M, Afzali A, Cross RK, et al. Economic outcomes of inflammatory bowel disease patients switching to a second anti-tumor necrosis factor or vedolizumab. Crohns Colitis. 2020;2(2):otaa31.
doi: 10.1093/crocol/otaa031
Cross RK, Naegeli AN, Harrison RW, et al. Disease burden and patient-reported outcome measures among ulcerative colitis patients according to therapy at enrollment into the Corrona IBD Registry. Gastroenterology. 2020;158(6 suppl 1):S725–6.
doi: 10.1016/S0016-5085(20)32493-8
Hunter T, Farrar M, Dong Y, Choong C, Naegeli AN. Medication use and healthcare resource utilization trends among adult ulcerative colitis patients in the United States: 2007–2017. Value Health. 2019;22(suppl 2):S180.
doi: 10.1016/j.jval.2019.04.784
Kochar B, Winn A, Barnes EL, Long MD, Kappelman M. The national experience with vedolizumab. Gastroenterology. 2018;154(6 suppl 1):S67–8.
doi: 10.1016/S0016-5085(18)30682-6
Naegeli A, Hunter T, Dong Y, Choong C, Crandall W. Impact of biologic treatment of ulcerative colitis on healthcare resource utilization in US patients. United Eur Gastroenterol J. 2019;7(suppl 8):61.
Nguyen J, Xia Q, Sharma N, Kapoor G, Ahmad H, Zhuo J. Trends in inflammatory bowel disease (IBD) related hospitalizations, emergency department visits, and intestinal resection among patients with IBD in the era of biologics. Gastroenterology. 2020;158(6 suppl 1):S731.
doi: 10.1016/S0016-5085(20)32507-5
Null KD, Xu Y, Pasquale MK, et al. Ulcerative colitis treatment patterns and cost of care. Value Health. 2017;20(6):752–61.
pubmed: 28577692
doi: 10.1016/j.jval.2017.02.005
Patel H, Khalid JM, Shah S, Shah R, Berger A. Early use of vedolizumab vs infliximab in biologic-naive patients with ulcerative colitis: a real-world analysis of healthcare utilisation. J Crohns Colitis. 2018;12(suppl 1):S385–6.
doi: 10.1093/ecco-jcc/jjx180.679
Perera S, Yang S, Stott-Miller M, Brady J. Analysis of healthcare resource utilization and costs after the initiation of biologic treatment in patients with ulcerative colitis and Crohn’s disease. J Health Econ Outcomes Res. 2018;6(1):96–112.
pubmed: 32685575
pmcid: 7309948
doi: 10.36469/9791
Pilon D, Ding Z, Muser E, et al. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. Curr Med Res Opin. 2020;36(8):1285–94.
pubmed: 32427006
doi: 10.1080/03007995.2020.1771293
Rubin DT, Griffith J, Zhang Q, Hepp Z, Keshishian A. The impact of intestinal complications on health care costs among patients with inflammatory bowel disease treated with anti-tumor necrosis factor therapies. Inflamm Bowel Dis. 2020;27:2.
Stewart MJ, Bessissow T, Gregor J, et al. Subcutaneously administered anti-TNFs for the treatment of ulcerative colitis: a retrospective, propensity score-matched, US health claims analysis. Adv Ther. 2021;38(7):4115–29.
pubmed: 34159558
doi: 10.1007/s12325-021-01818-3
Wolf DC, Puckett J, Setyawan J, Rabbat C, Sloan S, Kamal-Bahl S. Real-world treatment patterns and healthcare costs among US commercially insured adults initiating biologics for ulcerative colitis. United Eur Gastroenterol J. 2021;9(suppl 8):519–20.
Soriano A, Marchi S, Benedetti A, et al. Real-life evaluation of golimumab effectiveness and quality of life in patients with moderate-to-severe ulcerative colitis: the prospective Go-Care study. United Eur Gastroenterol J. 2021;9(suppl 8):504–5.
Bamias G, Kokkotis G, Gizis M, et al. Predictors of response to vedolizumab in patients with ulcerative colitis: results from the Greek VEDO-IBD cohort. Dig Dis Sci. 2022;67(3):1007–1017.
pubmed: 33751325
pmcid: 7942521
doi: 10.1007/s10620-021-06907-5
Bamias G, Xourafas V, Tsoukali E, et al. Treatment outcomes following administration of vedolizumab in patients with moderate to severe ulcerative colitis. United Eur Gastroenterol J. 2019;7(suppl 8):642.
Black CM, Yu E, McCann E, Kachroo S. Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data. PLoS ONE. 2016;11(2):e0149692.
pubmed: 26919745
pmcid: 4768958
doi: 10.1371/journal.pone.0149692
Casellas F, Robles V, Borruel N, et al. Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment. J Crohns Colitis. 2012;6(9):881–6.
pubmed: 22398074
doi: 10.1016/j.crohns.2012.01.019
Desmond AN, Shanahan F. Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. Ir J Med Sci. 2012;181(1):65–71.
pubmed: 21947686
doi: 10.1007/s11845-011-0760-y
Dignass A, Waller J, Cappelleri JC, et al. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ. 2020;23(4):415–27.
pubmed: 31858853
doi: 10.1080/13696998.2019.1707210
Dignass A, Waller J, Cappelleri JC, et al. P746 Living with ulcerative colitis in Germany: quantifying the socioeconomic impact of moderate to severe ulcerative colitis. J Crohns Colitis. 2019;13(suppl 1):S495.
doi: 10.1093/ecco-jcc/jjy222.870
Dignass A, Waller J, Cappelleri JC, et al. P782 Living with ulcerative colitis in Germany: quantifying the healthcare resource utilisation and direct healthcare costs associated with the treatment of moderate to severe ulcerative colitis in Germany. J Crohns Colitis. 2019;13(suppl 1):S512.
doi: 10.1093/ecco-jcc/jjy222.906
Eriksson C, Rundquist S, Lykiardopoulos V, et al. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therap Adv Gastroenterol. 2021;14:17562848211023386.
pubmed: 34276808
pmcid: 8255566
doi: 10.1177/17562848211023386
Gatopoulou A, Christodoulou DK, Katsanos KH, et al. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece. Eur J Gastroenterol Hepatol. 2021;21:21.
Khalili H, Everhov AH, Halfvarson J, et al. Healthcare use, work loss and total costs in incident and prevalent Crohn’s disease and ulcerative colitis: results from a nationwide study in Sweden. Aliment Pharmacol Ther. 2020;52(4):655–68.
pubmed: 32902894
pmcid: 7490827
doi: 10.1111/apt.15889
Lawton J, Achit H, Pouillon L, et al. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: a French large single-centre experience. United Eur Gastroenterol J. 2019;7(7):908–13.
doi: 10.1177/2050640619853448
Lo B, Vind I, Vester-Andersen MK, Bendtsen F, Burisch J. Direct and indirect costs of inflammatory bowel disease: ten years of follow-up in a Danish population-based inception cohort. J Crohns Colitis. 2020;14(1):53–63.
pubmed: 31076743
doi: 10.1093/ecco-jcc/jjz096
Lowenberg M, Duijvis NW, Ponsioen C, van den Brink GR, Fockens P, D’Haens GR. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis. Eur J Gastroenterol Hepatol. 2014;26(11):1240–6.
pubmed: 25171024
doi: 10.1097/MEG.0000000000000187
Mandel MD, Balint A, Golovics PA, et al. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: results from two referral centres. Dig Liver Dis. 2014;46(11):985–90.
pubmed: 25156871
doi: 10.1016/j.dld.2014.07.168
Mantzaris G, Gatopoulou A, Christodoulou D, et al. A real-world assessment of golimumab effect on quality of life, healthcare resource utilisation and work productivity in patients with ulcerative colitis in Greece: interim results from the GOLIFE study. J Crohns Colitis. 2019;13(suppl 1):S422.
doi: 10.1093/ecco-jcc/jjy222.735
Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105(12):2617–25.
pubmed: 20736936
doi: 10.1038/ajg.2010.345
Picker N, Bokemeyer B, Wilke T, Rosin L, Patel H. P404 Healthcare utilization and expenditures for patients with ulcerative colitis on advanced therapies in Germany. J Crohns Colitis. 2021;15(suppl 1):S411–2.
doi: 10.1093/ecco-jcc/jjab076.528
Picker N, Patel H, Wilke T, Rosin L, Bokemeyer B. P423 Treatment escalation and associated cost in German ulcerative colitis patients treated with advanced therapies. J Crohns Colitis. 2021;15(suppl 1):S427.
doi: 10.1093/ecco-jcc/jjab076.547
Bokemeyer B, Picker N, Wilke T, Rosin L, Patel H. P464 Steroid dependency in patients with ulcerative colitis treated with advanced therapies in a German real-world-setting. J Crohns Colitis. 2021;15(1):S455–6.
doi: 10.1093/ecco-jcc/jjab076.587
Pöllinger B, Schmidt W, Seiffert A, Imhoff H, Emmert M. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. Eur J Health Econ. 2019;20(2):195–203.
pubmed: 29362899
doi: 10.1007/s10198-017-0953-z
Sebastian S, Myers S, Argyriou K, et al. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019;50(6):675–83.
pubmed: 31456297
doi: 10.1111/apt.15456
Singh S, Andersen NN, Andersson M, Loftus EV Jr, Jess T. comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: a nationwide Danish cohort study. Clin Gastroenterol Hepatol. 2017;15(8):1218–25.
pubmed: 27913244
doi: 10.1016/j.cgh.2016.11.024
Wilke T, Groth A, Long GH, Tatro AR, Sun D. Rate of adverse events and associated health care costs for the management of inflammatory bowel disease in Germany. Clin Ther. 2020;42(1):130–43.
pubmed: 31883702
doi: 10.1016/j.clinthera.2019.11.012
Ylisaukko-Oja T, Torvinen S, Ventola H, et al. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab. Scand J Gastroenterol. 2019;54(6):726–32.
pubmed: 31203693
doi: 10.1080/00365521.2019.1627579
Torvinen S, Ventola H, Herrala S, Schmidt S, Ylisaukko-oja T, Voutilainen M. The economic burden of chronic inflammatory bowel disease patients in Finland. Value Health. 2018;21(suppl 3):S144.
doi: 10.1016/j.jval.2018.09.858
van Linschoten RCA, Visser E, Niehot CD, et al. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther. 2021;54(3):234–48.
pubmed: 34114667
pmcid: 8361769
doi: 10.1111/apt.16445
Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807–16.
pubmed: 20662837
doi: 10.1111/j.1365-2133.2010.09944.x
Svedbom A, Dahlen J, Mamolo C, et al. Economic burden of psoriasis and potential cost offsets with biologic treatment: a Swedish register analysis. Acta Derm Venereol. 2016;96(5):651–7.
pubmed: 26716136
doi: 10.2340/00015555-2329
Huynh L, Hass S, Peyrin-Biroulet L, et al. Real-world treatment patterns and physician preferences for biologics in moderate-to-severe inflammatory bowel disease: retrospective chart review in Europe. Crohns Colitis. 2022;4(1):otac001.
doi: 10.1093/crocol/otac001
Bokemeyer B, Picker N, Wilke T, Rosin L, Patel H. Inadequate response, treatment patterns, health care utilization, and associated costs in patients with ulcerative colitis: retrospective cohort study based on German claims data. Inflamm Bowel Dis. 2022;28(11):1647–57.
Bergqvist V, Holmgren J, Klintman D, Marsal J. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(11):1389–401.
pubmed: 35470449
pmcid: 9322578
doi: 10.1111/apt.16927
Causey E, Shah N, Slaughter C, et al. Non-adherence to self-injectable biologic therapy in IBD increases ED visits and hospitalizations S834. Am J Gastroenterol. 2021;116:386–7.
Choi J, Lukanova R, Ahmad H, et al. S3307 Unmet need of an oral treatment in moderate to severe ulcerative colitis: findings from international patient and physician survey. Am J Gastroenterol. 2021;116:S1363.
Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021. https://doi.org/10.1136/gutjnl-2021-326390 .
doi: 10.1136/gutjnl-2021-326390
pubmed: 34937767
Dubinsky MC, Betts KA, LaPensee K, et al. S694 Comparative efficacy and safety of ozanimod vs adalimumab and vedolizumab in patients with moderately to severely active ulcerative colitis. Am J Gastroenterol. 2021;116(suppl):S314.
doi: 10.14309/01.ajg.0000776308.71765.85
Eaton K, Duperrouzel C, Bhandari P, et al. POSB17 Ozanimod for the treatment of biologic-experienced patients with moderate-to-severe ulcerative colitis: results from a systematic literature review and network meta-analyses. Value Health. 2022;25(1):S27–8.
doi: 10.1016/j.jval.2021.11.127
Eaton K, Duperrouzel C, Bhandari P, et al. Ozanimod for induction treatment of moderate-to-severe ulcerative colitis: results from a systematic literature review and network meta-analyses. Presented at 16th Congress of the European Crohn’s and Colitis Organisation, July 2–3 and 8–10, 2021:Abstract DOP69.